TAS-102 in Extrapulmonary Neuroendocrine Carcinoma
Status:
Recruiting
Trial end date:
2023-08-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of drug, TAS-102
(trifluridine/tipiracil), in patients with extrapulmonary (outside the lung) high-grade
neuroendocrine cancer. TAS-102 demonstrated improved survival and tolerability in patients
with colorectal cancer and is currently approved by the FDA and marketed under the brand name
Lonsurf for the treatment of patients with metastatic colorectal cancer (mCRC). Recently, a
study evaluating TAS-102 showed a case of complete remission of high-grade NEC. Given the
safety profile of TAS-102 and the remarkable single agent activity in a disease with
otherwise dismal outcomes, we hope that TAS-102 may show tolerability and efficacy in
neuro-endocrine cancer and propose further exploration in patients with extrapulmonary
(outside the lung) high-grade neuroendocrine cancer.